Compare Flowserve Corporation Common Stock (FLS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flowserve Corporation Common Stock vs Organon & Co. Common Stock — how do they compare? Flowserve Corporation Common Stock trades at $69.78 (market cap $9.08B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Flowserve Corporation Common Stock is far larger — about 2.5× Organon & Co. Common Stock's market cap, and Flowserve Corporation Common Stock pays the higher dividend (1.23%). Which is the better fit depends on your goals — on Pluang, investors hold Flowserve Corporation Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| FLS | OGN | |
|---|---|---|
Market Cap | $9.08B | $3.62B |
Volume | 1,742,251 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $92.04 | $13.81 |
52-Week Low | $50.41 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.67B | $11.04B |
Dividend Yield | 1.23% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLS trades at $71.47, up 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Revenue for 2025 was $4.73 billion, with a net income margin of 8.01%. Recent news includes a new CFO appointment and a quarterly dividend declaration.
The outlook is mixed: strong fundamentals and a consensus price target of $90.75 suggest upside, but technical weakness and a high P/E of 24.9 pose risks. Key opportunities include strategic acquisitions and nuclear market exposure, while headwinds include weak organic sales and rising debt levels noted by analysts.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Flowserve Corporation Common Stock
Flowserve Corporation is a Texas-based manufacturer of engineered flow-control equipment, producing industrial pumps, mechanical seals, valves, and automation products through its Flowserve Pumps Division and Flow Control Division, serving the oil and gas, chemical, power, and water industries in more than 50 countries.
Read more on FLS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
